FOXO4-DRI
About
About FOXO4-DRI
FOXO4-DRI (FOXO4-D-Retro-Inverso) is a synthetic stapled peptide senolytic developed by de Keizer et al. (Nature Medicine, 2017). It disrupts the FOXO4–p53 interaction that keeps senescent cells alive, triggering apoptosis selectively in senescent cells. In mice, systemic administration reversed doxorubicin-induced liver damage, restored hair density in naturally aged mice, and improved fitness metrics. It has no FDA approval for human use and has not entered human clinical trials. It may be sold online as a research chemical without quality controls, purity verification, or dosing standards.
Science
Mechanism of Action
D-amino acid retro-inverso peptide that penetrates cells and competitively inhibits FOXO4 binding to p53, blocking the nuclear localization of p53 that senescent cells depend on for survival. This selectively restores p53-dependent apoptosis in senescent cells while sparing quiescent and proliferating normal cells. The stapled/D-amino acid design confers protease resistance and improved membrane penetration versus the native sequence.
Dosing
Typical Protocol
No established human dosing protocol. Research use only — no approved therapeutic form exists for human use. Consult a physician before considering any research-grade peptide of this class.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound has no FDA approval for human use in the United States and is not available through licensed US pharmacies or compounding channels. It has not completed the clinical trials required for FDA approval. It may be sold online as a research chemical without quality controls, purity verification, or dosing standards. Always consult a physician.
Evidence
Evidence Tier
Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.
No verified providers offering FOXO4-DRI yet
We audit new providers every week. Leave your email and we’ll let you know as soon as a Vial-verified provider starts offering FOXO4-DRI.
Free. We’ll only email when there’s a real match.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.